Skip to Content
MilliporeSigma
  • Management of paradoxical response in pediatric tubercular meningitis with methylprednisolone.

Management of paradoxical response in pediatric tubercular meningitis with methylprednisolone.

Middle East African journal of ophthalmology (2014-05-03)
Nitin Nema, Abha Verma, Kuldeep Singh, Virendra Mehar
ABSTRACT

Paradoxical response to anti-tubercular drugs remains a diagnostic dilemma. In India where tuberculosis is quite prevalent, paradoxical response to anti-tubercular treatment (ATT) is either misdiagnosed or under-diagnosed. We report two cases of optochiasmatic arachnoiditis due to paradoxical response in children suffering from tuberculous meningitis. Visual acuity was recorded as no light perception in all eyes of both patients while they were taking 4-drug ATT (isoniazid, rifampicin, pyrazinamide and ethambutol). However their systemic conditions did not worsen. They were treated with intravenous methylprednisolone for five days followed by systemic corticosteroids on a tapering dose for four weeks along with ATT. This case report highlights the importance of early recognition of this sight-threatening complication and timely, effective treatment to prevent permanent blindness.

MATERIALS
Product Number
Brand
Product Description

Supelco
Isoniazid, analytical standard, ≥99% (TLC)
Sigma-Aldrich
6α-Methylprednisolone, ≥98%
Rifampicin, European Pharmacopoeia (EP) Reference Standard
USP
Methylprednisolone, United States Pharmacopeia (USP) Reference Standard
Isoniazid, European Pharmacopoeia (EP) Reference Standard
Methylprednisolone, European Pharmacopoeia (EP) Reference Standard
Ethambutol for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Pyrazinecarboxamide
Sigma-Aldrich
Rifampicin, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
Rifampicin, suitable for plant cell culture, BioReagent, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
Ethambutol dihydrochloride, antimycobacterial
Ethambutol hydrochloride, European Pharmacopoeia (EP) Reference Standard
Pyrazinamide, European Pharmacopoeia (EP) Reference Standard